Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders

a technology of polypeptides and autoimmune disorders, applied in the field of polypeptides, immunotherapy, and drug development, can solve problems such as autoimmune diseases, and achieve the effects of preventing resistance to the second treatment, less frequent dosing, and reducing side effects

Inactive Publication Date: 2013-08-15
COMPUGEN
View PDF2 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0040]In another embodiment, the second therapeutic is Tysabri or another therapeutic for MS. In a further embodiment, C1ORF32 polypeptides, fragments or fusion proteins thereof is cycled with Tysabri or used during a drug holiday in order to allow less frequent dosing with the second therapeutic and reduce the risk of side effects such as PML and to prevent resistance to the second therapeutic.
[0041]In another embodiment, the second therapeutic agent is a small molecule that inhibits or reduces differentiation, proliferation, activity, and/or cytokine production and/or secretion by Th1, Th17, Th22, and/or other cells that secrete, or cause other cells to secrete, ...

Problems solved by technology

Despite these mechanisms, some self-reactive T cells may ‘escape’ and be present ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
  • Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
  • Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Description for Cluster H19011—1 (H19011)

[0331]The present invention relates to C1ORF32 polypeptides, and diagnostics and therapeutics based thereon.

[0332]It should be noted that these variants were originally disclosed in PCT Application No. WO2009 / 032845, owned in common with the present application, which is hereby incorporated by reference as if fully set forth herein.

[0333]Cluster H19011—1 (internal ID 76432827) features 2 transcripts and 5 segments of interest, the names for which are given in Tables 1 and 2, respectively. The selected protein variants are given in table 3.

TABLE 1Transcripts of interestTranscript NameH19011_1_T8 (SEQ ID NO: 1)H19011_1_T9 (SEQ ID NO: 2)

TABLE 2Segments of interestSegment NameH19011_1_N13 (SEQ ID NO: 9)H19011_1_N8 (SEQ ID NO: 10)H19011_1_N10 (SEQ ID NO: 11)H19011_1_N11 (SEQ ID NO: 12)H19011_1_N12 (SEQ ID NO: 13)

TABLE 3Proteins of interestProtein NameCorresponding TranscriptsH19011_1_P8 (SEQ ID NO: 4)H19011_1_T8 (SEQ ID NO: 1)H19011_1_P9 (SEQ ID N...

example 2

Cloning and Expression of C1ORF32 Extra Cellular Domain (ECD) Fused to Mouse Fc

[0354]The purpose of this analysis was to clone the C1ORF32 ECDs fused via its corresponding C′ terminus to mouse Fc (mFc), and to express the fused ECDs in HEK293T cells (ATCC-CRL-11268), in order to be further used for functional assessment of C1ORF32 ECD.

[0355]The coordinates of the cloned ECD are described in table 8:

TABLE 8FullECDproteinTranscriptProteinlengthCoordinatesnameNo.No.(aa)(aa)SEQ IDC1ORF32T8 (SEQP8 (SEQ2541-184SEQ IDID NO: 1)ID NO: 4)No. 19

[0356]The cloning of the fusion proteins (ECD_mFc) was done in two steps:

[0357]1. Cloning of ECD to pIRESpuro3 (a bicistronic mammalian expression vector, Clontech catalog number: 631619).

[0358]2. Subcloning of the mouse Fc IgG2a comprising hinge, CH2 and CH3 regions of murine immunoglobulin Cγ2a chain in frame to the C′ terminus of the ECD previously cloned into pIRESpuro3, from step1.

[0359]Cloning of ECD to pIRESpuro3

[0360]Cloning of the ECD (correspo...

example 3

Protein Production of C1ORF32 Extra Cellular Domain (ECD) Fused to Mouse Fc (C1ORF32_P8-V1-ECD_mFc)

[0369]Production in HEK293T Cells:

[0370]To produce C1ORF32 ECD fused to mouse Fc (C1ORF32_P8-V1-ECD_mFc), pool of transfected HEK293T cells stably transfected with the corresponding constructs described herein above, were used. The transfected cells, usually maintained in 10% serum supplemented medium, were transferred into serum free medium (EX-CELL293, SAFC) supplemented with 4 mM glutamine and selection antibiotics (5 ug / ml puromycin), and grown in suspension in shake flasks at 37° C., with agitation. The culture volume was increased by sequential dilutions until a production phase of 3-4 days carried out in 2 L spinners flasks. Medium from the spinners was harvested, cleared from cells by centrifugation, filtered through a 0.22 μm filter and kept at −20° C.

[0371]The C1ORF32_P8_V1_ECD_mFc protein was purified using nProtein A—affinity chromatography as described below.

[0372]Harvests...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Therapeuticaaaaaaaaaa
Login to view more

Abstract

This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.

Description

FIELD OF THE INVENTION[0001]This invention relates to a novel protein, and its variants, fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development.BACKGROUND OF THE INVENTION[0002]Induction of immune tolerance has long been considered the “holy grail” for autoimmune disease therapy. The immune system has the reciprocal tasks to protect the host against invading pathogens, but simultaneously to prevent damage resulting from unwanted reactions to self antigens. The latter part is known as immune tolerance and performed by a complex set of interactive and complementary pathways, which regulate immune responses. T cells have the ability to react to a variety of antigens, both self and nonself. Therefore, there are many mechanisms that exist naturally to eliminate potentially self-reactive responses—this is known as natural tolerance. The main mechanism for eliminating potential auto-reactive T cells occurs in the thymus and is known as cen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/47
CPCC07K14/4713A61K38/1709A61K47/42A61P1/00A61P1/16A61P1/18A61P13/12A61P17/06A61P19/02A61P19/04A61P19/06A61P25/00A61P25/28A61P27/02A61P27/06A61P29/00A61P37/00A61P37/02A61P9/14A61P3/10Y02A50/30A61P37/06A61K2035/122C07K2319/035A61K2039/577
Inventor ROTMAN, GALITHECHT, IRISLEVINE, ZURITPODOJIL, JOSEPH R.MILLER, STEPHEN D.
Owner COMPUGEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap